Terlipressin Increases Systemic and Lowers Pulmonary Arterial Pressure in Experimental Acute Pulmonary Embolism
- 15 February 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 48 (4), e308-e315
- https://doi.org/10.1097/ccm.0000000000004243
Abstract
Objectives: We investigated whether the vasopressin-analog, terlipressin induces systemic vasoconstriction and pulmonary vasodilation in a porcine model of acute pulmonary embolism. Design: Controlled, animal study. Setting: Tertiary medical center research laboratory. Subjects: Female pigs (n = 12, Cross of Land Race, Duroc, and Yorkshire ~ 60 kg). Interventions: Acute pulmonary embolism was induced by administration of three large autologous emboli. Animals then received four increasing doses of either terlipressin (n = 6) or vehicle (n = 6). Measurements and Main Results: Effects were evaluated in vivo at baseline, after pulmonary embolism and after each dose by invasive hemodynamic measures, transesophageal echocardiography, and blood analysis. Isolated pulmonary arteries were evaluated ex vivo in a myograph. Pulmonary embolism caused a four-fold increase in pulmonary vascular resistance (p < 0.0001) and a two-fold increase in mean pulmonary arterial pressure (p < 0.0001) compared with baseline. Terlipressin increased mean systemic blood pressure (28 ± 5 mm Hg; p < 0.0001) and systemic vascular resistance (1,320 ± 143 dynes; p < 0.0001) compared with vehicle. In the pulmonary circulation, terlipressin decreased mean pulmonary arterial pressure (–6.5 ± 1.8 mm Hg; p = 0.005) and tended to decrease pulmonary vascular resistance (–83 ± 33 dynes; p = 0.07). Terlipressin decreased cardiac output (–2.5 ± 0.5 L/min; p < 0.0001) and increased plasma lactate (2.7 ± 0.2 mmol/L; p < 0.0001), possibly indicating systemic hypoperfusion. A biomarker of cerebral ischemia, S100b, remained unchanged, suggesting preserved cerebral perfusion (0.17 ± 0.11 µg/L; p = 0.51). Ex vivo, terlipressin relaxed pulmonary and constricted mesenteric arteries. Conclusions: Terlipressin caused systemic vasoconstriction and pulmonary vasodilation in a porcine in vivo model of acute pulmonary embolism and vasorelaxation in isolated pulmonary arteries. Despite positive vascular effects, cardiac output declined and plasma lactate increased probably due to a predominantly systemic vasoconstrictor effect of terlipressin. These findings should warrant careful translation to the clinical setting and does not suggest routine use in acute pulmonary embolism.This publication has 36 references indexed in Scilit:
- S100B protein in serum is elevated after global cerebral ischemic injuryWorld Journal of Emergency Medicine, 2013
- Biochemical and myofilament responses of the right ventricle to severe pulmonary hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Differential Effects of Terlipressin on Pulmonary and Systemic Hemodynamics in Patients With Cirrhosis and Pulmonary HypertensionAngiology, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature reviewCritical Care, 2010
- Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot studyCritical Care, 2009
- Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertensionInteractive CardioVascular and Thoracic Surgery, 2007
- Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheepCritical Care Medicine, 2003
- The role of vasopressin in treating systemic inflammatory syndrome complicated by right ventricular failureCardiology in the Young, 1999
- Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertensionJournal of Hepatology, 1998